While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Ellie Crabtree, 22, from Cumbria, fell into a trap of emotional eating while caring for her father, Geoff, 59, was diagnosed ...

Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy outside of China.

Regeneron Pharmaceuticals said on Monday its experimental weight-loss drug combination helped preserve muscle mass in a ...

Amplify Weight Loss Drug & Treatment ETF THNR is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 51.9% from its 52-week low price of $18.56/share.

Vulnerable people have been warned about the emerging and potentially "devastating effects" of jabs used for weight loss.

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

Novo Nordisk’s semaglutide product to lose patent protection in China next year, according to L.E.K. Consulting.

Regeneron Pharmaceuticals said on Monday its experimental weight-loss drug combination helped preserve muscle mass in a ...

Humans have spent thousands of years experimenting with weight loss aids. While Ozempic and Wegovy may be generating ...

Legal battle over semaglutide between Novo Nordisk and Indian drugmakers will set precedent for future opportunities and ...